13561 Background: Bevacizumab (BV), a monoclonal antibody directed against vascular endothelial growth factor, provides a survival advantage (15.6 to 20.3 months) when added to first-line chemotherapy for metastatic colorectal cancer (metastatic CRC). Only a few trials have been conducted using BV as 2nd line chemotherapy. Methods: Sixteen patients with metastatic CRC refractory to first-line chemotherapy (oxaliplatin or irinotecan-based regimen) were enrolled. All patients, after progressing in first-line treatment, received the following regimen: BV: 5 mg/Kg* in 1000ml water for injection in 90min IV infusion plus irinotecan 125mg/m2 IV in 500ml NIS in 60min plus folinic acid 30mg/m2 and 5-fluorouracil 500mg/m2 IV bolus infusion. The schedule was repeated every 2 weeks. Fourteen men and 2 women entered the study with PS 0–1, median age of 66 years (range: 48–85). 11 patients (68.7%) had liver metastases, 3 patients (18.75%) had lung metastases and 4 patients (25%) had local tumor recurrence. All 16 patients were eligible for the study and received in total 174 (mean 10.8, range: 6–20) cycles. Six out of 16 patients (12.5%) had more than 2 metastatic sites (liver and local recurrence). Results: Six patients had partial responses (PRs) (37.5%), 4 patients had stable disease (SD) (25%) and the rest of the patients progressed (37.5%). The time to progression (TTP) was 6.4 months (range: 4–8), and the median survival was 9 (range: 5–12) months. The toxicity was mild and no toxic death was reported. Grade II toxicities were the following: epistaxis 4 patients (25%), anaemia 5 patients (31%), leukopenia 3 patients (18.7%), granulocytopenia 2 patients (12.5%) and 1 patient developed jaundice due to bile-duct obstruction. Conclusions: The bi-weekly administration of BV, irinotecan, leucovorin and 5-fluororacil is acceptable as 2nd line treatment in patients with metastatic CRC, with an overall response rate (PRs) of 37.5%, and SD of 25%. The TTP and survival were 6.4 and 9 months respectively. The study is ongoing and we expect to enrol more patients. No significant financial relationships to disclose.